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ABSTRACT
BACKGROUND: Neuraminidase inhibitors (NIs) are stockpiled and rec-
ommended by public health agencies for treating and preventing sea-
sonal and pandemic influenza. They are used clinically worldwide.
OBJECTIVE: To describe the potential benefits and harms of NIs for 
influenza in all age groups by reviewing all clinical study reports of 
published and unpublished randomised, placebo-controlled trials and 
regulatory comments.
METHODS
Search methods: We searched trial registries, electronic databases (to 22 
July 2013) and regulatory archives, and corresponded with manufac-
turers to identify all trials. We also requested clinical study reports. We 
focused on the primary data sources of manufacturers but we checked 
that there were no published randomised controlled trials (RCTs) from 
non-manufacturer sources by running electronic searches in the fol-
lowing databases: the Cochrane Central Register of Controlled Trials 
(CENTRAL), MEDLINE, MEDLINE (Ovid), EMBASE, Embase.com, PubMed 
(not MEDLINE), the Database of Reviews of Effects, the NHS Economic 
Evaluation Database and the Health Economic Evaluations Database.
Selection criteria: Randomised, placebo-controlled trials on adults and chil-
dren with confirmed or suspected exposure to naturally occurring influenza.
Data collection and analysis: We extracted clinical study reports and as-
sessed risk of bias using purpose-built instruments. We analysed the 
effects of zanamivir and oseltamivir on time to first alleviation of symp-
toms, influenza outcomes, complications, hospitalisations and adverse 
events in the intention-to-treat (ITT) population. All trials were spon-
sored by the manufacturers.
MAIN RESULTS: We obtained 107 clinical study reports from the European 
Medicines Agency (EMA), GlaxoSmithKline and Roche. We accessed com-
ments by the US Food and Drug Administration (FDA), EMA and Japanese 
regulator. We included 53 trials in Stage 1 (a judgement of appropri-
ate study design) and 46 in Stage 2 (formal analysis), including 20 osel-
tamivir (9623 participants) and 26 zanamivir trials (14,628 participants). 
Inadequate reporting put most of the zanamivir studies and half of the 
oseltamivir studies at a high risk of selection bias. There were inadequate 
measures in place to protect 11 studies of oseltamivir from performance 
bias due to non-identical presentation of placebo. Attrition bias was high 
across the oseltamivir studies and there was also evidence of selective 
reporting for both the zanamivir and oseltamivir studies. The placebo in-
terventions in both sets of trials may have contained active substances.
Time to first symptom alleviation. For the treatment of adults, oseltamivir 
reduced the time to first alleviation of symptoms by 16.8 hours (95% 
confidence interval (CI) 8.4 to 25.1 hours, P < 0.0001). This represents a 
reduction in the time to first alleviation of symptoms from 7 to 6.3 days. 
There was no effect in asthmatic children, but in otherwise healthy chil-
dren there was (reduction by a mean difference of 29 hours, 95% CI 12 
to 47 hours, P = 0.001). Zanamivir reduced the time to first alleviation of 
symptoms in adults by 0.60 days (95% CI 0.39 to 0.81 days, P < 0.00001), 
equating to a reduction in the mean duration of symptoms from 6.6 to 
6.0 days. The effect in children was not significant. In subgroup analysis 
we found no evidence of a difference in treatment effect for zanamivir 
on time to first alleviation of symptoms in adults in the influenza-infect-
ed and non-influenza-infected subgroups (P = 0.53).
Hospitalisations. Treatment of adults with oseltamivir had no significant 
effect on hospitalisations: risk difference (RD) 0.15% (95% CI -0.78 to 
0.91). There was also no significant effect in children or in prophylaxis. 
Zanamivir hospitalisation data were unreported.
Serious influenza complications or those leading to study withdrawal. In 
adult treatment trials, oseltamivir did not significantly reduce those 
complications classified as serious or those which led to study with-
drawal (RD 0.07%, 95% CI -0.78 to 0.44), nor in child treatment trials; 
neither did zanamivir in the treatment of adults or in prophylaxis. There 
were insufficient events to compare this outcome for oseltamivir in pro-
phylaxis or zanamivir in the treatment of children.
Pneumonia. Oseltamivir significantly reduced self reported, investigator-
mediated, unverified pneumonia (RD 1.00%, 95% CI 0.22 to 1.49); num-
ber needed to treat to benefit (NNTB) = 100 (95% CI 67 to 451) in the 
treated population. The effect was not significant in the five trials that 
used a more detailed diagnostic form for pneumonia. There were no 
definitions of pneumonia (or other complications) in any trial. No osel-
tamivir treatment studies reported effects on radiologically confirmed 
pneumonia. There was no significant effect on unverified pneumonia 
in children. There was no significant effect of zanamivir on either self 
reported or radiologically confirmed pneumonia. In prophylaxis, zana-
mivir significantly reduced the risk of self reported, investigator-medi-
ated, unverified pneumonia in adults (RD 0.32%, 95% CI 0.09 to 0.41); 
NNTB = 311 (95% CI 244 to 1086), but not oseltamivir.
Bronchitis, sinusitis and otitis media. Zanamivir significantly reduced the 
risk of bronchitis in adult treatment trials (RD 1.80%, 95% CI 0.65 to 2.80); 
NNTB = 56 (36 to 155), but not oseltamivir. Neither NI significantly re-
duced the risk of otitis media and sinusitis in both adults and children.
Harms of treatment. Oseltamivir in the treatment of adults increased 
the risk of nausea (RD 3.66%, 95% CI 0.90 to 7.39); number needed to 
treat to harm (NNTH) = 28 (95% CI 14 to 112) and vomiting (RD 4.56%, 
95% CI 2.39 to 7.58); NNTH = 22 (14 to 42). The proportion of partici-
pants with four-fold increases in antibody titre was significantly lower in 
the treated group compared to the control group (RR 0.92, 95% CI 0.86 
to 0.97, I2 statistic = 0%) (5% absolute difference between arms). Oselta-
mivir significantly decreased the risk of diarrhoea (RD 2.33%, 95% CI 0.14 
to 3.81); NNTB = 43 (95% CI 27 to 709) and cardiac events (RD 0.68%, 
95% CI 0.04 to 1.0); NNTB = 148 (101 to 2509) compared to placebo dur-
ing the on-treatment period. There was a dose-response effect on psy-
chiatric events in the two oseltamivir “pivotal” treatment trials, WV15670 
and WV15671, at 150 mg (standard dose) and 300 mg daily (high dose) 
(P = 0.038). In the treatment of children, oseltamivir induced vomiting 
(RD 5.34%, 95% CI 1.75 to 10.29); NNTH = 19 (95% CI 10 to 57). There 
was a significantly lower proportion of children on oseltamivir with a 
four-fold increase in antibodies (RR 0.90, 95% CI 0.80 to 1.00, I2 = 0%).
Prophylaxis. In prophylaxis trials, oseltamivir and zanamivir reduced 
the risk of symptomatic influenza in individuals (oseltamivir: RD 3.05% 
(95% CI 1.83 to 3.88); NNTB = 33 (26 to 55); zanamivir: RD 1.98% (95% CI 
0.98 to 2.54); NNTB = 51 (40 to 103)) and in households (oseltamivir: RD 
13.6% (95% CI 9.52 to 15.47); NNTB = 7 (6 to 11); zanamivir: RD 14.84% 
(95% CI 12.18 to 16.55); NNTB = 7 (7 to 9)). There was no significant ef-
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fect on asymptomatic influenza (oseltamivir: RR 1.14 (95% CI 0.39 to 
3.33); zanamivir: RR 0.97 (95% CI 0.76 to 1.24)). Non-influenza, influenza-
like illness could not be assessed due to data not being fully reported. 
In oseltamivir prophylaxis studies, psychiatric adverse events were in-
creased in the combined on- and off-treatment periods (RD 1.06%, 95% 
CI 0.07 to 2.76); NNTH = 94 (95% CI 36 to 1538) in the study treatment 
population. Oseltamivir increased the risk of headaches whilst on treat-
ment (RD 3.15%, 95% CI 0.88 to 5.78); NNTH = 32 (95% CI 18 to 115), 
renal events whilst on treatment (RD 0.67%, 95% CI -2.93 to 0.01); NNTH 
= 150 (NNTH 35 to NNTB > 1000) and nausea whilst on treatment (RD 
4.15%, 95% CI 0.86 to 9.51); NNTH = 25 (95% CI 11 to 116).
AUTHORS’ CONCLUSIONS: Oseltamivir and zanamivir have small, 
non-specific effects on reducing the time to alleviation of influenza 
symptoms in adults, but not in asthmatic children. Using either drug 
as prophylaxis reduces the risk of developing symptomatic influenza. 
Treatment trials with oseltamivir or zanamivir do not settle the ques-
tion of whether the complications of influenza (such as pneumonia) 
are reduced, because of a lack of diagnostic definitions. The use of 
oseltamivir increases the risk of adverse effects, such as nausea, vom-
iting, psychiatric effects and renal events in adults and vomiting in 
children. The lower bioavailability may explain the lower toxicity of 
zanamivir compared to oseltamivir. The balance between benefits 
and harms should be considered when making decisions about use 
of both NIs for either the prophylaxis or treatment of influenza. The in-
fluenza virus-specific mechanism of action proposed by the produc-
ers does not fit the clinical evidence.
This is the abstract of a Cochrane Review published in the Cochrane 
Database of Systematic Reviews (CDSR) 2014, issue 4. Art. No.: 
CD008965. DOI: 10.1002/14651858.CD008965.pub4 (http://onlineli-
brary.wiley.com/doi/10.1002/14651858.CD008965.pub4/abstract). For 
full citation and authors’ details, see reference 1.
The full text is freely available from: http://onlinelibrary.wiley.com/
doi/10.1002/14651858.CD008965.pub4/pdf
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COMMENTS
Although neuraminidase inhibitors are available through the Brazilian 
public healthcare system, the indications for their use, made by infectious 
disease specialists, geriatricians, otolaryngologists and pulmonologists, 
are still very limited. During the 2009 pandemic, use of these drugs in-
creased significantly, and then progressively decreased in the period fol-
lowing it. This happened because of unawareness of the drug’s availabil-
ity, its mode of action and, especially, late diagnosis of influenza among 
Brazilian patients, which reduces the drug’s performance. 
Regarding the review presented above, a number of sources of bias can 
be seen, which impede analysis of its conclusions. Some of these are 
described below, in order to illustrate the difficulty in interpreting the 
results. The first of these is the difference in the number of participants 
between the groups that used oseltamivir and zanamivir, such that 
there were almost twice as many patients in the latter group. It should 
also be highlighted that zanamivir is not available in Brazil and that it is 
used much more in East Asian countries such as Japan. 
Another important source of bias that should be pointed out in analyz-
ing the use of these inhibitors both for prophylaxis and for treatment is 
the notable methodological differences that are known to exist in using 
these drugs, such that the diagnostic criteria (mostly clinical) are rarely 
complied with. Indications for the treatment should be made within the 
first 48 hours (ideally 36 hours), but this rarely happens. The abstract 
presented here does not mention any comparisons of how and when 
the drug was first administered. 
There is also a significant difference in drug performance evaluations 
between situations in which presence of a disease is confirmed through 
laboratory tests or through clinical criteria alone. The abstract presented 
does not give any information in this regard. From the data presented 
and the format in which these data were analyzed, it cannot be safely 
affirmed that the conclusions presented correctly represent the efficacy 
of these drugs for preventing and treating influenza. 
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